Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca AB, European Regulatory Affairs
Femme et Homme Max 99 ans
AstraZeneca AB, European Regulatory Affairs
MAJ Il y a 4 ans
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS)[PLATO – A Study of PLATelet inhibition and Patient Outcomes]
The primary objective of this study is to test that AZD6410 is superior to clopidogrel for prevention of vascular events (death from vascular causes, MI, stroke) in patients with non-ST or ST elevatio...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB, European Regulatory Affairs
MAJ Il y a 4 ans
A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation
Primary safety objective: To evaluate the dose-response relationship for QT effects of AZD1305 Primary efficacy objective: To demonstrate a dose-response relationship for AZD1305 given intravenously f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB, European Regulatory Affairs
MAJ Il y a 4 ans
A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Background Therapy in Patients with Stable Coronary Artery Disease with Additional Detailed Assessment of Cardiopulmonary Function
The primary objective of this study is to determine the onset and offset of antiplatelet effect of AZD6140 compared to clopidogrel by evaluation of: • The percent inhibition of platelet aggregation (I...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations